Browsing by Author "Sertesen Camoz, Elif"

Now showing 1 - 3 of 3

Citation - WoS: 1
Citation - Scopus: 1
Evaluating the Prognostic Role of Glucose-to Ratio in Patients With Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors in First Line: A Study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)
(Springer Int Publ AG, 2025) Bolek, Hatice; Kuzu, Omer Faruk; Sertesen Camoz, Elif; Sim, Saadet; Sekmek, Serhat; Karakas, Hilal; Urun, Yuksel
Purpose Identifying prognostic indicators for risk stratification in metastatic renal cell carcinoma (mRCC) is crucial for optimizing treatment strategies and follow-up plans. This study aims to investigate the prognostic role of the glucose-to-lymphocyte ratio (GLR) in patients with mRCC receiving tyrosine kinase inhibitors (TKIs) as first-line therapy. Methods A retrospective cohort study was conducted using data from the Turkish Oncology Group Kidney Cancer Consortium Database. GLR was calculated by dividing the fasting glucose (mmol/L) by the lymphocyte count (x109/L). We categorized patients into two categories based on their median GLR level. Results The analysis included a total of 598 patients. We found that progression-free survival (PFS) was significantly longer in the GLR-low group, with a median PFS of 15.05 months (95% CI 12.7-17.4) compared to 7.79 months (95% CI 6.6-9.0) in the GLR-high group (p < 0.001). Multivariate analysis identified GLR as an independent risk factor for poor PFS (HR 1.39, 95% CI 1.12-1.72; p = 0.003). Overall survival (OS) was also significantly longer in the GLR-low group, with a median OS of 38.47 months (95% CI, 30.9-46.0) compared to 24.15 months (95% CI 18.0-30.2) in the GLR-high group (p = 0.001). GLR was an independent predictor for OS in multivariate analysis (HR 1.45, 95% CI 1.12-1.86; p = 0.004). Conclusion The GLR can be a valuable prognostic marker for glucose metabolism and systemic inflammatory status in this patient population. Our research highlights the potential prognostic value of GLR in patients with mRCC receiving TKIs, indicating its potential as a useful tool for clinical decision-making.
Prognostic Role of Smoking in Metastatic Renal Cell Carcinoma in Real-World Data From the Turkish Oncology Group Kidney Cancer Consortium (TKCC)
(Nature Portfolio, 2026) Bolek, Hatice; Sertesen Camoz, Elif; Kuzu, Omer Faruk; Karakas, Hilal; Sim, Saadet; Sekmek, Serhat; Urun, Yuksel
Smoking has been implicated as a potential factor influencing cancer progression and outcomes in various malignancies, including metastatic renal cell carcinoma (mRCC). This study aimed to evaluate the effect of smoking status on treatment outcomes in mRCC patients, with a focus on metastatic sites. This retrospective cohort study utilized data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC). The primary endpoint of the study was overall survival (OS) across metastatic sites. A total of 779 patients were included, of whom 464 (58.1%) were former/current smokers. Smoking status did not significantly affect OS in the overall cohort. However, in the bone metastatic subgroup, former/current smokers exhibited worse OS compared to never smokers (33.9 vs. 22.1 months; p = 0.005). Multivariate Cox regression analysis showed that former/current smoking was an independent predictor for OS in patients with bone metastasis (former/current smoker vs never smoker HR 1.44, 95% CI 1.05-1.99; p = 0.026) and bone-only metastasis (former/current smoker vs never smoker HR 4.44; 95% CI 1.27-15.55; p = 0.020) after adjusting for confounding factors. Smoking is an independent predictor of poor survival in mRCC patients with bone metastases, highlighting the organ-specific effects of smoking on cancer progression. Further research is needed to explore underlying mechanisms and evaluate outcomes in the context of modern therapies.
Citation - WoS: 1
Citation - Scopus: 1
Sunitinib in Metastatic Renal Cell Carcinoma: Clinical Outcomes Across Risk Groups in a Turkish Oncology Group Kidney Cancer Consortium
(Wiley, 2025) Bolek, Hatice; Kuzu, Omer Faruk; Sertesen Camoz, Elif; Sim, Saadet; Sekmek, Serhat; Karakas, Hilal; Urun, Yuksel